Axsome Therapeutics Reports First Quarter 2017 Financial Results
09 mai 2017 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, May 09, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system...
Axsome Therapeutics Announces Full Exercise of Underwriter’s Option to Purchase Additional Shares
29 mars 2017 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, March 29, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics to Present at the 16th Annual Needham Healthcare Conference
23 mars 2017 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, March 23, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics Announces Pricing of Its Public Offering of Common Stock
21 mars 2017 09h19 HE
|
Axsome Therapeutics, Inc.
NEW YORK, March 21, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics Announces Proposed Public Offering of Common Stock
20 mars 2017 16h06 HE
|
Axsome Therapeutics, Inc.
NEW YORK, March 20, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update
07 mars 2017 16h35 HE
|
Axsome Therapeutics, Inc.
Interim analysis results from two Phase 3 trials of AXS-02 in separate indications anticipated in 2H 2017 Top-line results from the Phase 3 STRIDE-1 trial of AXS-05 in treatment resistant depression...
Axsome Therapeutics to Present at the 29th Annual ROTH Conference
27 févr. 2017 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, Feb. 27, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics to Present at the 2017 RBC Capital Markets Global Healthcare Conference
13 févr. 2017 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, Feb. 13, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics to Present at the 2017 BIO CEO & Investor Conference
07 févr. 2017 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, Feb. 07, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics to Present at Biotech Showcase 2017
04 janv. 2017 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, Jan. 04, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...